This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): Abciximab, C7E3 Fab.
Description: REOPRO (Abciximab) is an antithrombotic that inhibits platelet aggregation. REOPRO is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3 that binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin (avb3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Partners: Johnson & Johnson
Pink Sheet In Brief: Lilly/Centocor ReoPro
Pink Sheet In Brief: Centocor's ReoPro
Additional information available to subscribers only: